Stable sales for OLYSIO during the third quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stable sales for OLYSIO during the third quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to 796 MUSD, of which 671 MUSD were sales in the USA. Medivir’s royalties based on sales for the third quarter are calculated from the highest royalty tier and currency conversion from USD to Euro is based on the YTD exchange rate. The royalty amounted to 516,4 MSEK (56,2 MEUR). OLYSIO®                      Sales in MUSD global net sales Market Q3 2014 Q2 2014 Q1 2014 US 671 725 291 RoW 125 106 63 Total global 796 831 354 net sales MUSD Medivir will publish its third quarter report on November 20, 2014 at 8.30 CET followed by a Conference call for investors, analysts and the media at 14.00 CET. More information about the Conference call / Webcast will be posted at www.Medivir.com For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.55 CET on 14 October2014. About Simeprevir (Olysio®) Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen‐Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. Simeprevir was approved in September 2013 in Japan, in November 2013 in Canada and the U.S., in March 2014 in Russia and in July 2014 in Mexico and Australia. In May 2014 simeprevir was granted marketing authorization by the European Commission (EC) for the treatment of adult patients with genotype 1 or genotype 4 chronic HCV. Following the EMA approval, it has so far been made available in several EU countries in conjunction with reimbursement. Simeprevir (Olysio) is marketed under the trade name Sovriad® in Japan and Russia, Galexos™ in Canada and Olysio® in the U.S. and European Union. About Medivir Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, Olysio. In addition, revenues for sales of Olysio in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science, targeting different disease areas. The company’s current research and development focus is within infectious diseases, osteoarthritis, neuropathic pain and oncology. Medivir is listed on the Nasdaq OMX Stockholm Mid Cap List.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 39

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 97

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 97

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 64

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 247

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 119

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 93

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading

Top 5 Most Recently Viewed Articles

Ethyl Alcohol Market Poised for Growth Amid AI Innovations

Updated Category News Views 195

Ethyl Alcohol Market Growth Fueled by AI Innovations The ethyl alcohol market is on the brink of significant growth as industries worldwide evolve. Recent trends suggest a promising expansion, with an expected increase of USD 16.94 billion from 2024 to 2028, based on insightful reports. This upward trajectory will stem from several key factors, such as an ample supply of...

Continue Reading
Meghan's Exciting Gourmet Brand Launch: A New Era Begins

Updated Category News Views 344

Meghan, Duchess of Sussex, Launches Gourmet Brand In a fresh and exciting venture, Meghan, Duchess of Sussex, proudly presents her new brand, As Ever. This lifestyle brand focuses on offering beautifully crafted gourmet products meant to enhance daily living. Known for her commitment to quality and authenticity, Meghan has partnered with skilled artisans to ensure each...

Continue Reading
Osisko Development Completes US$24.2 Million Private Placement

Updated Category News Views 64

Osisko Development Corp. hit a key funding milestone back in 2024 when it pulled together around US$24.2 million through a non-brokered private placement. This wasn’t just another run-of-the-mill financing—traders were watching closely as Osisko’s ambitious plans for the gold sector began to take shape. Private Placement Breakdown: What You Need to Know The first...

Continue Reading
Tesla's Stock Adjustment: Analyst Insights on AI and Valuation

Updated Category News Views 261

Tesla Faces New Analyst Ratings Amid Market Dynamics Tesla Inc. shares have seen a downward shift recently due to a change in rating from a prominent investment bank. Following Morgan Stanley's latest assessment, the stock's rating transitioned from Overweight to Equal-Weight. This reevaluation stems from concerns surrounding valuation, as new lead analyst Andrew Percoco...

Continue Reading
FTAI Aviation Ltd. Announces Strong Q3 2025 Performance Review

Updated Category News Views 328

FTAI Aviation Ltd. Financial Highlights for Q3 2025 FTAI Aviation Ltd. (NASDAQ: FTAI) revealed its financial results for the third quarter of 2025, demonstrating significant growth and profitability during this period. The company's net income attributable to shareholders reached a remarkable $114 million, which translates to an earnings per share (EPS) of $1.11, marking...

Continue Reading